J
Joshua J. Meeks
Researcher at Northwestern University
Publications - 217
Citations - 8212
Joshua J. Meeks is an academic researcher from Northwestern University. The author has contributed to research in topics: Bladder cancer & Cancer. The author has an hindex of 42, co-authored 193 publications receiving 6407 citations. Previous affiliations of Joshua J. Meeks include Veterans Health Administration & Children's Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
Sam S. Chang,Bernard H. Bochner,Roger Chou,Robert Dreicer,Ashish M. Kamat,Seth P. Lerner,Yair Lotan,Joshua J. Meeks,Jeff M. Michalski,Todd M. Morgan,Diane Zipursky Quale,Jonathan E. Rosenberg,Anthony L. Zietman,Jeffrey M. Holzbeierlein +13 more
TL;DR: This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.
Journal ArticleDOI
Prostate Cancer, Version 1.2016
James L. Mohler,Andrew J. Armstrong,Robert R. Bahnson,Anthony V. D'Amico,Brian J. Davis,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Michael E. Hurwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Joshua J. Meeks,David F. Penson,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Stan Rosenfeld,Edward M. Schaeffer,Ted A. Skolarus,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +31 more
TL;DR: This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Journal ArticleDOI
Bladder cancer, version 5.2017: Clinical practice guidelines in oncology
Philippe E. Spiess,Neeraj Agarwal,Rick Bangs,Stephen A. Boorjian,Mark K. Buyyounouski,Peter E. Clark,Tracy M. Downs,Jason A. Efstathiou,Thomas W. Flaig,Terence W. Friedlander,Richard E. Greenberg,Khurshid A. Guru,Noah M. Hahn,Harry W. Herr,Christopher J. Hoimes,Brant A. Inman,Masahito Jimbo,A. Karim Kader,Subodh M. Lele,Joshua J. Meeks,Jeff M. Michalski,Jeffrey S. Montgomery,Lance C. Pagliaro,Sumanta K. Pal,Anthony L. Patterson,Elizabeth R. Plimack,Kamal S. Pohar,Michael P. Porter,Mark A. Preston,Wade J. Sexton,Arlene O. Siefker-Radtke,Guru Sonpavde,Jonathan D. Tward,Geoffrey Wile,Mary A. Dwyer,Lisa A. Gurski +35 more
TL;DR: The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Journal ArticleDOI
A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Joshua J. Meeks,Joaquim Bellmunt,Bernard H. Bochner,Noel W. Clarke,Siamak Daneshmand,Matthew D. Galsky,Noah M. Hahn,Seth P. Lerner,Malcolm David Mason,Thomas Powles,Cora N. Sternberg,Guru Sonpavde +11 more
TL;DR: Cisplatin-based neoadjuvant combination chemotherapy is an established standard, improving overall survival in MIBC and pathologic complete response appears to be an intermediate surrogate for survival, but this finding requires further validation.
Journal ArticleDOI
Pediatric Testicular Torsion Epidemiology Using a National Database: Incidence, Risk of Orchiectomy and Possible Measures Toward Improving the Quality of Care
TL;DR: The modern incidence of testicular torsion as well as the current rates of orchiectomy and attempted testicular salvage are determined, and the risk factors for testicular loss are identified.